Advisory Board

ICER is fortunate to have the support of a Governance Board and an Advisory Board consisting of national experts in health care policy. The Governance Board has fiduciary responsibility for the overall operations of ICER, while both the Governance Board and Advisory Board provide important strategic counsel to ICER’s leadership team.  Our three core programs, CTAF, Midwest CEPAC, and New England CEPAC, have their own stakeholder advisory boards tasked with topic selection, policy implementation and strategic counsel.

Governance and Advisory Board Members (PDF)

Robert W. Dubois, MD, PhD

Chief Science Officer

National Pharmaceutical Council


Stephen Friedhoff, MD

Senior Vice President, Clinical Strategy and Programs



Jon Gavras, MD

Senior Vice President, Chief Medical Officer

Prime Therapeutics


Vivian Herrera

VP, Head US HE&OR and HE&OR Payer Strategy, US Health Economics & Outcomes Research and Medical Access

Novartis Pharmaceuticals Corporation


Bryan Johnstone, PhD

Vice President, Global HEOR



Andreas Kuznik

Senior Director, Health Economics and Outcomes Research

Regeneron Pharmaceuticals


Carolyn Langer, MD, JD, MPH

Chief Medical Officer

Office of Medicaid (MassHealth), Commonwealth of Massachusetts


Martin Marciniak, PhD

Vice-President, U.S. Medical Affairs, Customer Engagement, Value, Evidence, and Outcomes



Kendra Martello, JD

Senior Director, Public Policy, Government Affairs & Public Policy

Mallinckrodt Pharmaceuticals


Michael Sherman, MD, MBA, MS

Senior Vice President and Chief Medical Officer

Harvard Pilgrim Health Care


Susan Shiff, PhD, MBA

Senior Vice President, Center for Observational and Real World Evidence

Merck & Co., Inc.


Sean Sullivan, PhD, MSc

Professor and Dean

University of Washington School of Pharmacy


Marcus Thygeson, MD

Chief Health Officer

Bind Benefits


John Watkins, PharmD, MPH, BCPS

Pharmacy Manager, Formulary Development

Premera Blue Cross